Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 132-145
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 119
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 45
Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 30
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
Shouyan Deng, Yibo Zhang, Huanbin Wang, et al.
Cell (2024) Vol. 187, Iss. 9, pp. 2305-2323.e33
Closed Access | Times Cited: 15
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers
Scott Strum, Mads Hald Andersen, Inge Marie Svane, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 8
Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery
Charlotte Stutzmann, Jiaxi Peng, Zhaoguan Wu, et al.
Cell Reports Methods (2023) Vol. 3, Iss. 6, pp. 100511-100511
Open Access | Times Cited: 18
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
Padma Akkapeddi, Takamitsu Hattori, Imran Mahmood Khan, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 28
Open Access | Times Cited: 15
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward
Clinical Cancer Research (2023) Vol. 29, Iss. 24, pp. 5012-5020
Open Access | Times Cited: 14
Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response
Wenbo Ning, Yan Sheng, Yingquan Song, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Ramil Khusnutdinov
Reviews and Advances in Chemistry (2025)
Closed Access
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Adith S. Arun, David Liarakos, Gaurav Mendiratta, et al.
PubMed (2025) Vol. 25, Iss. 1-2, pp. 5-5
Closed Access
Antigen discovery for the development of cancer immunotherapy
Ryuhjin Ahn, Yufei Cui, Forest M. White
Seminars in Immunology (2023) Vol. 66, pp. 101733-101733
Open Access | Times Cited: 12
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance
Ruth Nussinov, Hyunbum Jang
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 231-253
Closed Access | Times Cited: 12
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Kuen Kuen Lam, Siew Heng Wong, Peh Yean Cheah
Cells (2023) Vol. 12, Iss. 4, pp. 631-631
Open Access | Times Cited: 10
Immune vulnerabilities of mutant KRAS in pancreatic cancer
Noah Cheng, Robert H. Vonderheide
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 928-936
Open Access | Times Cited: 10
Defining the Cell Surface Cysteinome Using Two-Step Enrichment Proteomics
Tianyang Yan, Lisa M. Boatner, Liujuan Cui, et al.
JACS Au (2023) Vol. 3, Iss. 12, pp. 3506-3523
Open Access | Times Cited: 9
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS mutations
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top